Clinical Trial: Currently Recruiting
SanBio, Inc. / Sunovion (PDF): A Double-Blind, Controlled Phase 2b Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke (NCT02448641)
This is a double-blind, sham-surgery controlled study of stereotactic, intracranial injection of SB623 cells in patients with fixed motor deficits from ischemic stroke. The study will be conducted at approximately 65 sites in the United States.
SB623 cells are bone-marrow-derived stromal cells that have been transiently transfected with the intercellular domain of the human Notch-1 gene.
If you are interested to learn more about this trial, click the pdf flyer link above or contact Principal Investigator, Dr. Achal S. Achrol.
For at least 20% of our cavernoma patients, the condition is inherited (“familial”). While cavernomas may also occur sporadically, we now understand that most of the time it may not be as obvious that the disease was inherited without specialized genetic testing for what is called “autosomal dominant inheritance pattern with variable expression and incomplete penetrance.”
Three specific molecular alterations have been identified in genetic analyses of our cavernoma patients. These alterations affect the formation of junctions between the cells that line the inside of our blood vessels (called “endothelial” cells), resulting in thin-walled, dilated blood vessels with abnormal gaps between the cells. The three molecular alterations that have been associated with cavernoma are called KRIT1 (aka CCM1), MGC4607 (aka CCM2), and PDCD10 (aka CCM3). The fact that the disease does not form in every patient who inherits these alterations suggests there are other molecular pathways that can stabilize these abnormalities. Further research into targeting these molecular pathways is ongoing at the Cavernoma Institute, and offers much promise for the development of medical therapies that may one day prevent new cavernoma formation and minimize the need for surgical interventions.
For example, advanced precision therapy trials that may be an option for cavernoma patients include targeted inhibition of RhoA by simvastatin and targeted inhibition of ROCK by fasudil, as well as cyclic adenosine monophosphate-elevating drugs, all treatments that may help promote the stability of blood vessels. Other precision therapy approaches that may protect against the symptomatic progression of cavernomas include anti-angiogenic and immune-therapies, for example sorafenib, which may target VEGF receptors and ERK signaling.
Carotid Stenosis Research
If your carotid artery stenosis has not caused a stroke or transient ischemic attack (TIA), you may be eligible to participate in a new research study (CREST-II) aimed at determining whether medicines or procedures like stenting and surgery are better to treat your carotid artery disease.
Schedule a consultation at the Pacific Stroke and Aneurysm Center if you would like to be evaluated to participate in a research trial.